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Abstract
In the past decade, hundreds of mutations have been found in the SCN1A (sodium 
voltage-gated channel α subunit 1) gene in the epileptic patients. The functioning of the 
SCN1A gene products is intensively studied in the neuroscience field. The loss-of-function 
mutations of the SCN1A gene are the causative factor of Dravet syndrome, an intractable 
epilepsy syndrome. With the loss-of-function Na
v
1.1 (the protein encoded by SCN1A 
gene), the selective dysfunction of the inhibitory parvalbumin (PV) interneurons impairs 
the balance of excitatory and inhibitory synaptic inputs to the downstream neurons, and 
causes the hyperexcitability of the neuronal network. The underlying mechanism is that 
the axon initial segments (AISs) of inhibitory parvalbumin interneurons predominantly 
express Na
v
1.1, particularly in the proximal end of the AISs. The deficiency of Na
v
1.1 
weakens the excitability of the inhibitory parvalbumin neurons and leads to the hyper-
excitability of the neuronal network. The sodium channel blockers, one category of the 
antiepileptic drugs (AEDs) that specifically block the activity of VGSCs, may potentially 
worsen the defect of Na
v
1.1 of the PV interneurons in the patients with the SCN1A gene 
loss-of-function mutations, aggravate the clinical manifestation, and increase the seizure 
frequency of those patients.
Keywords: epilepsy, Dravet syndrome, voltage-gated sodium channel, axon initial 
segment, interneuron
1. Introduction
Voltage-gated sodium channels (VGSCs) play an essential role in the generation of the action 
potentials, which are the primary way for the communication between the excitable cells, 
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particularly the neurons. The action potential is the fast method to collect the afferent sensory 
information and to relay the efferent motor commands in the nervous system. The pathways 
to transfer the action potentials rely on the organized expression and the proper functioning 
of VGSCs [1]. The genetic mutations that cause the defected expression of VGSCs or the mal-
function of the altered VGSC gene products impair the physiological function of conduction 
pathway [2], nerve nuclei [3], and cortical neurons [4]. Epilepsy is a common multifactorial 
neurological disease that is caused by both environmental and genetic factors [5]. Several 
ion-channel genes are evidently associated with epilepsy, such as SCN1A [6], SCN2A (sodium 
voltage-gated channel α subunit 2) [7], SCN8A (sodium voltage-gated channel α subunit 8) 
[8], GABRA1 (gamma-aminobutyric acid type A receptor α 1 subunit), GABRG2 (gamma- 
aminobutyric acid type A receptor γ2 subunit) [9], and KCNA2 (potassium voltage-gated 
channel subfamily A member 2) [10]. Those genes predominantly control at least one critical 
event in a specific neuron type or/and a particular subcellular region during the physiological 
functioning of the neurons. The irreversible dysfunction of those gene products leads to the 
permanent pathological alteration of the targeted neurons and increases the susceptibility to 
seizures.
2. VGSC α subunit 1 and Dravet syndrome
Na
v
1.1 existing in the majority in the brain and was labeled at the soma and dendrites 
of the neurons in the early studies, referred as Na + channel subtype RI, or Type I Na(+) 
channel alpha-subunit [11, 12]. Nowadays, more than 1000 mutations [13] have been found 
in the SCN1A genes. They have been believed as the causative factors of generalized epi-
lepsy with febrile seizure plus (GEFS+) [14], Dravet syndrome (severe myoclonic epilepsy 
of infancy—SMEI) [15], and migraine [16]. The SCN1A gene could be called as “an epilepsy 
gene” because of its close relationship with febrile seizures and the epilepsies with ante-
cedent febrile seizures [13]. Dravet syndrome has been intensively studied within SCN1A 
gene mutations, the related functional analysis [6, 17], and the high phenotype-genotype 
correlations to SCN1A gene [18]. It is a rare disease of 1-to-40,000 incidence in the USA at 
estimate and 1-per-15,700 incidence in northern California with evidence [19]. The debili-
tating clinical progress goes from the “febrile stage” in the first year of life, the “worsening 
stage” until the age of 6 years, to the “stabilization stage” in the rest of life [20]. The clinical 
case may have the family history of epilepsy or febrile seizures, no previous medical history 
(an apparently normal baby), and the generalized or unilateral febrile seizures beginning 
in the first year followed by myoclonic jerks, partial seizures, atypical absence, and status 
epilepticus. The patients progressively lose the neurological functioning, such as retarded 
psychomotor development, ataxia, pyramidal signs, interictal myoclonus, intellectual defi-
ciency or cognitive impairment, and personality disorders [21]. A French pediatrician, Dr. 
Charlotte Dravet, first described the rare disease in 1978 [22], and in 2001, Lieve Claes team 
in Belgium found seven SCN1A gene mutations in SMEI patients, including four frame-
shift and truncation mutations (c.657-658delAG, c.3299-3300insAA, c.5010-5013delGTTT, 
and c.5536-5539delAAAC), one nonsense mutation (c.664C>T), one splice donor mutation 
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(IVS22+1G>A), and one missense mutation (c.2956C>T) [15]. The subsequent genotyping 
studies indicated that the SCN1A gene truncation mutations appeared with the higher 
frequency in Dravet syndrome than in the milder phenotype of febrile seizure-related 
epilepsy, and furthermore, the cognitive function impairment of the SCN1A-positive epi-
lepsy patients also associated with the truncation variants, regardless of age at seizure 
onset [23]. Those truncation mutations severely alter the molecular structure of sodium 
channel, reduce the expression amount of the SCN1A gene products, and hence severely 
impact the Na
v
1.1-VGSC functioning in the neurons. The underlying pathogenic mecha-
nism of one-allele truncation could be due to the haploinsufficiency (the loss of the half 
amount of Na
v
1.1) [24] or a dominant-negative effect that represents the mutated proteins 
(truncated Na
v
1.1) negatively affect wild-type products (normal allele-expressed Na
v
1.1) 
[25]. However, the truncated Na
v
1.1 protein in the human brain sample of a patient with 
Dravet syndrome was not detected, while the mRNA of both the wild-type and the trun-
cation mutations was equally expressed. It was explained as the endoplasmic reticulum-
associated degradation of the misfolded or misassembled protein caused the absence of 
the truncated Na
v
1.1 protein [26]. Therefore, the lower expression of the Na
v
1.1 protein, 
the haploinsufficiency of SCN1A gene, should be the main pathogenesis of SCN1A trunca-
tion mutations. The remaining mutations of SCN1A gene causing Dravet syndrome are 
the missense and splice-site mutations that mistakenly code the amino acids building the 
pore-forming region of VGSC [27] and cause the severe impairment of the function and 
electrophysiological properties of the Na
v
1.1 protein (VGSC α subunit 1) [28–30].
Both the haploinsufficiency and the pore-forming mutations of SCN1A gene impact the VGSC 
function severely because structurally the Na
v
1.1 protein constructs the main part of VGSC 
complex. This type of sodium channel is made up of a large pore-forming glycosylated α 
subunit and one or two small β subunits non-covalently (β1 or β3) or covalently (β2 or β4) 
associated with the large α subunit. The α subunit is coded by SCN1A-SCN11A gene (Na
v
1.1-
Na
v
1.9 protein) and responsible for the generation of transmembrane sodium current. The β 
subunits regulate the electrophysiological properties of sodium current (the gating and kinet-
ics of α subunits) and the subcellular location or expression of α subunit [31]. Those muta-
tions disable the main part of VGSC, α subunit, by either the insufficient amount of subunit 
for the complex resembling or the structurally altered subunit to make the malfunctioning 
complex. The primary structure of the VGSC α subunit contains four internally repeated 
transmembrane domains (I–IV). Each domain includes six α-helical transmembrane segments 
(S1–S6). The S1–S4 segments are the voltage-sensing module, and the S5–S6 segments are the 
pore-forming module (D400, E755, K1237, and A1529 in each of four homologous domains, 
forming part of the selectivity filter [32]). Nine members of VGSC α subunits (Na
v
1.1–Na
v
1.9) 
have been identified with similar complex structure and functional properties [33]. Na
v
1.1 is 
tetrodotoxin (TTX)-sensitive and could be blocked by nanomolar concentrations of TTX [34]. 
Na
v
1.1, Na
v
1.2 (SCN2A), Na
v
1.3 (SCN3A), and Na
v
1.6 (SCN8A) primarily locate in central ner-
vous system and are the primary subtypes of VGSCs in the neurons of brain and spinal cord 
[35]. Four subtypes of VGSC α subunits in the central nervous system express in the specific 
neuron types and the specific subcellular location [36, 37].
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3. Animal models and pathogenic mechanism of Dravet syndrome
Based on the genotyping results that the SCN1A-gene truncation mutations are found in the 
large percentage of patients with Dravet syndrome [18], the scientists produce the genetic mod-
els to disrupt the SCN1A gene by truncation mutations. They successfully duplicate the clini-
cal features in mouse models of Dravet syndrome, such as spontaneous and frequent seizures, 
impaired neurological function, and premature death [4, 38, 39]. Yu et al. at the University of 
Washington, USA, first replaced the last exon (Exon 26) of SCN1A gene of 129/SvJ and C57BL/6 
mice with neomycin-resistance gene cassette to make the truncation at the domain IV, S3 seg-
ment of Na
v
1.1 protein. By measuring whole-cell sodium currents of the dissociated neurons, 
the authors found a substantial decrease in the sodium current amplitude and other significant 
alteration of electrophysiological features, which indicated the reduced amount of the functional 
VGSCs in Scn1a−/− and Scn1a+/− interneurons. They also confirmed that in those GABAergic 
inhibitory interneurons the VGSC subtype Na
v
1.3 was upregulated to compensate the reduced 
functional Na
v
1.1 protein, without the apparent increase of Na
v
1.2 and Na
v
1.6 [4]. The group 
of Mistry at the Vanderbilt University, USA, generated another SCN1A gene truncation mice 
in 2014 by disrupting Exon 1 of the SCN1A gene. They measured the electrophysiological fea-
tures of acutely dissociated hippocampal neurons and found that the sodium channel density 
was lower in GABAergic interneurons of the Scn1a+/− mice. Furthermore, the sodium channel 
density in excitatory pyramidal neurons of Scn1a+/− mice was also elevated, which potentially 
correlated with age-dependent lethality. Although the phenotype severity was variable due to 
the factors of strain and age of mice with Dravet syndrome, the findings first emphasized the 
contribution of pyramidal neuron hyperexcitability during the pathological process in the study 
of animal model [38]. Both of the studies point out that the imbalance of electrophysiological 
activities of the excitatory (pyramidal neurons) and the inhibitory neurons (GABAergic inter-
neurons) is the fundamental pathogenesis to cause the intractable seizures in mice with Dravet 
syndrome that had the SCN1A gene truncation mutations.
Furthermore, the Ogiwara group in Japan provided the results from an SCN1A truncation 
knock-in mouse model, which displayed the specific subcellular region of Na
v
1.1 deficiency 
in those dysfunctional inhibitory neurons. By inserting the nonsense mutation R1407X into 
mouse SCN1A gene, the authors found that the truncated Na
v
1.1 protein was not detectable 
in either Scn1aRX/RX or Scn1a+/RX knock-in mice. In the neocortex of those developing mouse 
brain, only a subpopulation of the neocortical neurons, the parvalbumin-positive interneu-
rons (PV neurons), had the Na
v
1.1 immunostaining signals, predominantly at the axon initial 
segments (AISs). Consequently, the Scn1a+/RX neocortical PV interneuron (GAD67+), fast-spik-
ing interneurons, displayed the spike amplitude decrement during prolonged spike trains 
[6, 39]. That important study proved the specific functional defect of the PV neurons and the 
critical pathophysiological role of the PV neurons in Dravet syndrome. Moreover, in an in-
vivo animal study, using the advanced techniques, such as optogenetics, local field potential, 
and multiunit activity signals recording, the authors surprisingly found that the spontaneous 
cortical activity of Scn1a+/− mice did not alter in vivo. Although after sacrificing those mice, 
they could recognize the seizure-related pathological changes in the brain slices, such as the 
hypoexcitability of the parvalbumin and somatostatin interneurons, the rapid propagation of 
epileptiform activity, and the pathogenic synaptic adaptions [40]. Therefore, we could reason 
Ion Channels in Health and Sickness60
that the interneuron hypoexcitability should exist much earlier than the electroencephalogra-
phy (EEG)-positive findings in the patients with Dravet syndrome.
The other type of SCN1A gene mutations causing Dravet syndrome is the missense muta-
tion in the pore-forming region of VGSC. Another group in Japan, using gene-driven ENU 
mutagenesis technique, generated Scn1a-targeted rats carrying a missense mutation N1417H 
miscoding the amino acid in the third pore region of VGSC [29]. The clinical feature of the 
N1417H rat was milder than that of truncation Scn1a mouse models. The rat had neither spon-
taneous seizures nor apparent pathological abnormality in the brain in the earlier life, but at 
postnatal week 5, after a hot water bath about 3.5 min, the rats exhibited clonic seizures. The sus-
ceptibility to hyperthermia-induced seizures increased with age. The hippocampal GABAergic 
interneurons of the N1417H rats were hypoexcitable with the reduced action potential ampli-
tude. The authors believed that the clinical phenotype of the N1417H rat was close to that of 
generalized epilepsy with febrile seizure plus (GEFS+) [41]. However, the common pathogenic 
mechanism of the truncation mutations and the pore-forming region mutations of Na
v
1.1 is 
the selective interneuron dysfunction and hypoexcitability due to the Na
v
1.1 deficiency or mal-
function. The results from the study of the N1417H rat enhance the hypothesis that the selec-
tive impairment of the PV interneurons is the primary pathogenesis of febrile seizure–related 
epilepsy syndrome, the clinical spectrum from GEFS+ to Dravet syndrome [18].
4. Inhibitory interneurons and the features for their specialties
During the processing of the neuronal activities in the central nervous system, the simul-
taneous excitation and inhibition assure the proper excitability of the neuronal network 
and the precise control of the neuronal functions. Inhibition in the cortex is generated by 
the GABAergic neurons, which make up about 20% of the cortical neuronal population. 
Compared with the pyramidal cells (excitatory neurons), they have the smaller size and much 
shorter-range projects of the axon to form the local circuit with the nearby neurons and layers 
[42]. The interneurons could generate the long-lasting currents, the faster reaction to stimuli, 
and the higher-frequency signal transmission. The inhibition in a neuronal microcircuit could 
apply at the right millisecond (timing) and with the precise amount (dosing) exactly matching 
the inhibitory demand [42, 43]. The defects of GABAergic neuronal function have been identi-
fied as the contributive factors to the neuronal diseases, such as epilepsy, schizophrenia, and 
autism spectrum disorders [44, 45]. The cell therapy strategy of the GABAergic neurons for 
epilepsy was applied in several significant studies of epileptic model and stem cells [44, 46]. In 
the studies of animal models of Dravet syndrome, the constitutive Na1.1 knockout selectively 
impacted the functioning of the inhibitory parvalbumin interneurons, spared the detectable 
dysfunction of the excitatory neurons, and caused by the imbalance of excitation and inhibi-
tion, which led to the spontaneous and intractable seizures [4, 38, 39]. On the background of 
the Na
v
1.1 knockout specifically in the PV neurons, the addition of Na
v
1.1 knockout specifi-
cally in the excitatory neurons could alleviate the clinical manifestation of Dravet syndrome 
[6] and potentially re-balance the excitatory and inhibitory neuronal activity. Based on those 
results, we can understand that the balancing status of inhibitory neurons and excitatory neu-
rons functioning is the determinant of the clinical phenotypes of Drave syndrome.
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The several types of inhibitory interneurons are called as “basket” cells, “chandelier” cells, 
and “Martinotti” cells due to their morphological features. Because of their morphological 
advantages, they connect and inhibit the particular compartment of principal neurons [42]. 
The “basket” cells have the highly branched axons that innervate the target somas and the 
proximal dendrites of pyramidal neurons, as the axonal branches appear like baskets sur-
rounding the pyramidal neurons. In hippocampus CA1, the parvalbumin-expressing bas-
ket cells (PVBCs, 26% of CA1 interneurons) are more than the cholecystokinin-expressing 
basket cells (CCKBCs, 12% of CA1 interneurons) [47]. The PVBCs place 99% output to 
connect the pyramidal cells and the rest 1% output to form the gap junctions and reciprocal 
synaptic connections onto themselves or other interneurons generating gamma oscillation 
[48, 49]. The “chandelier” cells that are also parvalbumin positive have the “cartridges” 
shape of the axonal arbors that selectively inhibit the AISs of pyramidal cells, and hence 
they are also called the axon-axonic cells providing precise control of the action potential 
generation of pyramidal cells [48, 50, 51]. The axon-axonic cells represent about 15% of 
all PV hippocampal interneurons [47]. The “Martinotti” cells target the apical dendritic 
tuft and express the somatostatin and calbindin but not parvalbumin or vasoactive intes-
tinal peptide (VIP) [52]. In the hippocampus, the rest of PV cells is “Bistratified” cells, 
which represent about 25% of PV hippocampal interneurons with the PV-immunosignal 
on the somatodendritic compartments. In the PVBCs, the Na+ channels are sparse in the 
dendrites where K+ channels predominate. The Na+ channels cluster at the AIS of PVBCs. 
In fact, 99% of PVBC Na+ channels are located in the axonal compartment [53]. The unique 
feature of the high-density distribution of Na+ channels at the PVBC AISs determines the 
fast-spiking pattern of the PVBCs, which typically generate uniform, non-changing, and 
high-frequency discharge [54].
5. AIS and VGSC
Axon initial segment (AIS) contains the high density of sodium and potassium channels; the 
scaffolding protein ankyrin G (AnkG), βIV spectrin, and extracellular matrix–binding pro-
tein neurofascin; and the ion channel–associated protein FGF14 (fibroblast growth factor 14). 
Those are necessary to help the sodium channels locate and cluster at the AIS [55]. The AIS has 
the lowest threshold for action potential initiation because of the highest density of sodium 
channels when compared with somatodendritic compartment [53]. The proper functioning 
of AIS is essential for action potential initiation and adaptive cell excitability of both pyrami-
dal cells (excitatory neurons) and GABAergic interneurons (inhibitory neurons). Many factors 
regulate the function of the sodium channels at the AIS [55, 56]. First, the distinctive VGSC 
α subunit types express in specific neuronal types and the particular regions of AIS. In the 
human brain tissue, the fluorescence signals of Na
v
1.1 have been found at the thinly AnkG-
labeled AIS, which putatively belongs to the interneurons, while Na
v
1.2 and Na
v
1.6 are located 
at the AISs of human cortical pyramidal cells [51]. Na
v
1.6, the low-threshold sodium channel 
subtype, accumulates at the distal end of AIS of cortical pyramidal cells, which is responsible 
for generating the action potentials. The high-threshold Na
v
1.2 locates at the proximal end of 
AIS of cortical pyramidal cells, which regulates the action potential backpropagation [57]. The 
Ion Channels in Health and Sickness62
Na
v
1.1 has been found at the proximal end of AIS of cortical and cerebellar interneurons and 
the axons of main olfactory bulb neurons. The Na
v
1.1 immunosignals predominantly outline 
the axons of the parvalbumin-positive neurons [58]. The action potential threshold of Na
v
1.6 
is more hyperpolarized (15–25 mV lower) than that of both Na
v
1.2 and Na
v
1.1. Unlike Na
v
1.6 
more likely producing a persistent current, Na
v
1.1 and Na
v
1.2 show the apparent use-depen-
dent inactivation (higher than 20 Hz) [59, 60]. Therefore, the accumulated Na
v
1.6 at the distal 
end of the AIS facilitates the action potential initiation, while Na
v
1.2 and Na
v
1.1 subunits gath-
ering at the proximal end of AIS prevent the high-frequency firing of nerve cells backward.
Second, the molecule complex at AIS, composed of the ion channels (Kv1, T-type Ca2+ channel) 
and ligands (FGF14, VGSC β subunit 1, and βIV spectrin), directly or indirectly cooperates 
with Na+ channel and regulates the neuronal excitability. FGF14 could directly interact with 
the C-terminal of VGSC α subunit (Na
v
1.1, Na
v
1.2, Na
v
1.6) in the transfected HEK293 cells [61]. 
The fgf14−/− mice showed the significantly reduced number of the PV interneurons, but the 
pyramidal neuron number was unchanged in the CA1 hippocampus region. This change coop-
erated with the reduced GAD67 immunosignals in PV cell soma, the reduced gamma oscilla-
tions in CA1 stratum radiatum layer, and the deficits in spatial working memory, which was 
displayed by the eight-arm maze test [62]. Because the FGF14 is a complementary protein of 
Na
v
1.1, Na
v
1.2, and Na
v
1.6 at the AIS [61, 63, 64], the pyramidal cells of the fgf14−/− mice should 
have been affected as well due to the loss of FGF14:Na
v
1.6 and FGF14:Na
v
1.2 complex. Why are 
the PV cells the first or most to be affected by FGF14 protein defect or the FGF14:Na
v
1.1 com-
plex deficiency? What makes the FGF14:Na
v
1.1 critical for the excitability of the PV cells and 
finally impact on the number of the live PV cells? Similarly, the Na
v
1.1-predominant proximal 
end of the AIS only occupies a small part of the AIS of the PV cells, and why the Na
v
1.1 defi-
ciency impairs the PV cell functions dramatically and causes the Dravet syndrome? We expect 
the promising studies and explanation in future. Other molecules in the AIS complex, such as 
VGSC β subunit and AnkG, have been recognized as the ligand or the anchoring protein to 
stabilize the VGSC α subunit and regulate their functions at the AIS [65, 66].
Third, the location and the size of the AIS can be adapted for the neuronal activity and the 
long-term plasticity. The longer AIS, the higher excitability of the neuron. The more proxi-
mal location of the AIS, the higher excitability of the neuron. The chronic depolarization of 
the dissociated neurons moved the AIS distally and then decreased the neuronal excitability. 
The dynamic regulation of the AIS location through activity-dependent structural reorgani-
zation relied on the activation of T-type voltage-gated calcium channels and the elevation of 
intracellular [Ca2+] [67]. On the other hand, the experiments to eliminate the sensory stimuli 
made the AIS longer with little change in Na+ channel density and ion channel composition at 
the AIS, which increased the whole cell Na+ current, and the neuronal excitability. However, 
those adaptive responses also depend on the neuronal types due to the distinctions of the 
AIS location of different neurons under the standard conditions [67]. In the PV interneu-
rons, the action potentials are generated at 20 μm away from the soma at the AIS [53], which 
means the proximal part of the AIS of the PV neurons locates even closer than 20 μm since 
the action potential generates at the beginning of the distal part of the AIS. The AIS of the 
PV neurons locates more proximal than the AIS of pyramidal cells that has been observed at 
20–60 μm from the soma by ankyrin G staining [68]. Using specific neuronal marker labeling, 
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Höfflin et al. saw the AISs of the pyramidal neurons were significantly longer than that of the 
interneurons [69]. Based on those findings of the PV interneurons and their AISs, neuroscien-
tists may have many interests in the regulatory mechanisms of Na
v
1.1 cooperative function-
ing and adaptive response to the neuronal activity, coupling with the dynamic plasticity of 
the PV interneuron AIS.
With the specialized output structures of PV interneurons (“basket” or “chandelier car-
tridge”), the interactions of the PV interneurons (PVBCs or chandelier cells) and the pyrami-
dal cells, inhibitory synapses, are accordingly subject to the dynamic regulation of adaptive 
neuronal functioning and the AIS plasticity. The chandelier cell axon terminals only contact 
the AISs of pyramidal cells and have three to five boutons per cartridge. The innervation pat-
terns are similar at different postnatal age. Multiple chandelier cells (four at estimate) connect 
one pyramidal cell, while one chandelier cell contacts 35–50% of pyramidal cells in the tra-
versed area by its axonal arbor [70]. The inhibitory synapses exist in the innervation of a chan-
delier cell to the pyramidal cell by nature. The innervation could be visible by labeling the 
chandelier cells (pre-synaptic component) with the marker of GABA membrane transporter 1 
(GAT1) or parvalbumin (PV) and labeling the post-synaptic pyramidal cell AIS with GABA
A
 
receptor α
2
 subunit. The structures and functioning status of those synapses keep updated to 
meet the dynamic developmental demands [71, 72] and are impacted in the specific areas by 
pathological conditions, such as epilepsy and schizophrenia [73, 74].
6. Treatment to Dravet syndrome and therapeutic response
Dravet syndrome is an intractable epileptic encephalopathy with the unfavorable outcome. 
The most commonly used AEDs for patients with Dravet syndrome include valproate, topira-
mate, benzodiazepines, stiripentol, and potassium bromide [22]. Because the high percentage 
of patients with Dravet syndrome have the SCN1A gene mutations [18], some AEDs should 
be avoided, such as the sodium channel blockers (lamotrigine [75] and carbamazepine [76]), 
to prevent the inhibition of the rest Na
v
1.1 functioning in PV interneurons. Guerrini et al. 
retrospectively reviewed 21 Dravet syndrome cases and found that 80% (17) patients with 
lamotrigine treatment showed >50% increase in seizure frequency for 2 months and then 
ceased the lamotrigine treatment [75]. In a large-sized (276 patients) study, Shi et al. showed 
the evidence that the treatment of carbamazepine to Dravet syndrome was either not effective 
(<50% seizure reduction) or worsening the clinical condition (>25% increase in seizure fre-
quency) [76]. Considering the high percentage of SCN1A gene mutations in Dravet syndrome 
and the potential risk of worsening seizures by AEDs, the clinicians recommend a screening 
test to detect the SCN1A gene mutations for the suspected patients with Dravet syndrome (the 
initially normal infants suffering from prolonged, recurrent, febrile, and hemiclonic seizures 
induced by bathing). The purpose of the screening test is to optimize AEDs and rehabilita-
tion therapy [77, 78] at the earlier stage of the disease. The test can be done with the direct 
sequencing of the coding exons of SCN1A gene or multiplex ligation-dependent probe ampli-
fication [79]. There are an increasing number of the adult patients with the intractable sei-
zures, who finally are diagnosed with Dravet syndrome. They may retain the partial seizures, 
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secondary generalized clonic-tonic seizures [80], and intellectual disability, which are all not 
the characteristic symptoms for the diagnosis of Dravet syndrome. It is not occasional that 
those underdiagnosed patients with Dravet syndrome have been treated with sodium chan-
nel blockers, such as carbamazepine and oxcarbazepine, for years. However, the attempt to 
withdraw the treatment of carbamazepine or oxcarbazepine from those adult patients is still 
risky for seizure frequency rebound, withdrawal-related seizure, and sudden death [81].
Valproate is the most frequently used AED to treat Dravet syndrome. Shi et al. found that 
87% of SCN1A mutation patients and 78% of SCN1A negative patients were using valpro-
ate. About 52% of SCN1A mutation patients and 41% SCN1A negative patients responded to 
the valproate treatment (>50% reduction in seizure frequency). Bromide (potassium bromide 
and sodium bromide) was the most effective AED. About 41% SCN1A mutation patients and 
21% SCN1A negative patients used bromide with 71% and 94% responder rate, respectively. 
The SCN1A negative patients had the significantly higher responder rate to bromide, when 
compared with SCN1A mutation patients [76]. Bromide therapy was usually used in combi-
nation with valproate (100%), topiramate (91%), clobazam (75%), levetiracetam (66%), and 
so on. After 3 months of treatment, 81% of patients (26/32) had >50% reduction in seizure 
frequency, and after 12 months of treatment, 47% of patients (15/32) still maintained >50% 
seizure reduction [82]. Verapamil add-on treatment was reported in two pediatric patients 
with Dravet syndrome. They gained the long-period (13 months and 20 months) seizure free 
with the verapamil dosage of 1.5 mg/kg/day. As a result of a long period of seizure free, the 
patient’s neurological and cognitive function improved significantly [83]. Levetiracetam add-
on treatment was proved as an effective therapy to Dravet syndrome by an open-label clinical 
trial. The dose was titrated up to 50–60 mg/kg/day within 5- to 6-week up-titration phase and 
maintained in a 12-week evaluation phase. The responder rate ranged from 44.4 to 64.2% var-
ied by the distinctive seizure types [84]. Stiripentol is one of the commonly used medications 
for Dravet syndrome. Because of its fair tolerability profile, stiripentol is frequently added 
within valproate and clobazam and maintained in the triple long-term therapy remedy (96% 
patients). However, the effectiveness of stiripentol is not ideal for seizure control. De Liso 
et al. evaluated 54 patients with Dravet syndrome after stiripentol maintenance at the dose 
of 35–50 mg/kg/day. They found that 96% of patients continued to have clonic or tonic-clonic 
seizures (38% of patients had the seizure frequency more than three times per month, 40% of 
patients remained seizure frequency once to three times per month, and the rest of patients 
remained yearly seizures) [85]. Balestrini and Sisodiya observed stiripentol add-on treatment 
in 13 patients with Dravet syndrome. Only 23% of patients (3/13) gained >50% reduction in 
seizure frequency, 23% of patients (3/13) showed seizure worsening, 23% of patients (3/13) 
showed no change, and 15% of patients (2/13) showed <50% reduction in seizure frequency 
[86]. Obviously, the responder rate or effectiveness of the pharmacological treatment of 
Dravet syndrome is not ideal. The clinicians also assessed the vagus nerve stimulation for 
Dravet syndrome treatment. Fulton et al. placed the vagus nerve stimulation for 12 patients 
with Dravet syndrome and assessed the seizure control after 6 months. Nine of them showed 
>50% reduction in generalized tonic-clonic seizures, and four of them showed the cognitive 
function improvement [87]. Neuroscientist screened the potential therapeutic agents and 
tested their effectiveness in vivo in the experimental setting. Scn1Lab zebrafish model was 
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used for the fast drug screening for SCN1A-mutated Dravet syndrome. Baraban et al. applied 
the molecules in the swimming bath of the mutant or control zebrafish, tracked the swimming 
velocity and behaviors of the zebrafish, and identified clemizole that could inhibit seizure 
behavior and electrographic seizures of the mutant zebrafish [88]. Ohmori et al. found that 
the intraperitoneal methylphenidate could improve the behavior (hyperactivity, anxiety-like 
behavior, and spatial learning impairments) of N1417H-Scn1a mice and significantly sup-
press the hot bath-induced seizures [89]. Similar to the results from human case studies, the 
N1417H-Scn1a mice showed the good therapeutic response to potassium bromide (reduced 
seizure duration) without significant impairment in motor coordination [90].
7. Discussion
Epilepsy is a chronic neurological disease worldwide, which jeopardizes the patients’ lives, bur-
dens the patients’ family and caregivers, and requires to be concerned with the increasing atten-
tion to the affordable therapies, the effectiveness of current treatment strategies, and the social 
support to the patients and the caregivers. The pharmaceutical therapy (the application of AEDs) 
is the most commonly used strategy to fight against epilepsy. However, 30% of epilepsy patients 
are resistant to the optimized AED treatment without obvious precipitating factors [95]. Dravet 
syndrome might be an intractable and adverse form of extremity, which requires the multiple 
AED remedy (Table 1) and resistant to many AEDs over time [22]. The two major mechanisms 
are responsible for the resistance to AEDs in chronic epilepsy. One is the desensitization or 
modification of the molecular targets of AEDs during the chronic pathological process (frequent 
and recurring seizures), and the other is the overexpression of multidrug transporters, such as 
P-glycoprotein [96]. The sodium channel blocker is one of the main classes of AEDs. The genetic 
polymorphisms of the molecular targets, VGSC α subunits, are significantly associated with 
AED resistance. The genetic variant of SCN2A IVS7-32A>G (rs2304016) did not alter the SCN2A 
mRNA expression quantity or the exon splicing but had statistically significant association with 
AED resistance [97]. The calcium channel is also the therapeutic target of some AEDs, such as 
retigabine and ethosuximide (ETS). The genetic association study of drug-resistant epilepsy in 
the Chinese Han population displayed that the specific haplotype of the gene-coding calcium 
voltage-gated channel subunit alpha1 A (CACNA1A) was the risk factor for AED resistance [98]. 
How do those polymorphisms facilitate the desensitization of the AED target? We still need 
the extended functional studies to reveal the underlying mechanism. For instance, a significant 
cell functional study of the human brain samples collected from the surgery of hippocampal 
sclerosis resection provided the evidence of one mechanism of AED resistance (the modification 
of the cellular target of AEDs). Some categories of AEDs (benzodiazepines and barbiturates) 
stimulate the gamma-aminobutyric acid (GABA
A
) receptor and increase the intracellular concen-
tration of chloride and synaptic inhibition. However, the expected GABAergic response of the 
treated pyramid cells relies on the proper functioning and the normal expression profile of chlo-
ride transporters (Na-K-2Cl cotransporter NKCCl and K-Cl cotransporter KCC2). Otherwise, 
the GABA
A
 receptor activation depolarize the postsynaptic compartments, which contributes 
to the epileptiform activity in the stimulated pyramidal cells. In fact, in the temporal lobe epi-
lepsy biopsy tissue, a small group of pyramidal cells downregulated the expression of KCC2 and 
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Agent or 
medication
Main action for treatment Dosage in the 
treatment
Responder rate 
(>50% reduction)
Retain 
period 
(year)
Retain combination 
remedy
Aggravation rate 
(>25% increase)
Cause of death 
(SE or SUDEP*)
Valproate (VPA) Na+ Ca+ channel ↓ GABA ↑ 
GLUT ↑ [91]
30–50 mg/kg/d 
[92]
52 and 41% [76] VPA + Br VPA + CZP 
+ Br
VPA + CLB + Br [81]
SUDEP [92]
Topiramate (TPM) Na+ Ca+ channel ↓ GABA ↑ 
GLUT ↑ [91]
7.5–15 mg/kg/d 
[92]
57 and 33% [76] 17% [82]
Clobazam (CLB) GABA ↑ [91] 0.2–1 mg/kg/d 
[92]
44 and 48% [76] VPA + Br VPA + CLB 
+ Br [81]
SUDEP [92]
Clonazepam 
(CZP)
GABA ↑ [91] 0.03–0.1  
mg/kg/d [92]
44 and 38% [76] VPA + Br VPA + CZP 
+ Br [81]
Zonisamide (ZNS) Na+ Ca+ channel ↓ [91] 36 and 38% [76] 44% [82]
Phenobarbital 
(PHB)
GABA ↑ [91] 29 and 35% [76]
Phenytoin (PHT) Sodium channel blocker [91] 10 and 29% [76] 50% [82]
Stiripentol (STP) GABAergic enhancer [93] 35–50 mg/kg/d 
[85]
23% [86] 5 [86] VPA + CLB CLB + 
TPM VPA + TPM [86]
23% [86] 6% [82]
Bromide (Br) Stabilize the excitable 
membrane through 
hyperpolarization [94]
30–70 mg/kg/d 
[76]
30–106  
mg/kg/d [82]
71 and 94% [76]
81% [82]
2.5 [76]
2 [82]
VPA + Br VPA + CZP 
+ Br
VPA + CLB + Br [76]
VPA + TPM + CLB 
[82]
Levetiracetam 
(LEV)
Act as a neuromodulator 50–60 mg/kg/d 
[84]
44–64% [84] VPA + TPM + LEV 
[84]
VPA + CLB + LEV 
[84]
5% [82]
Lamotrigine 
(LTG)
Sodium channel blocker [91] 2.5–12.5 
mg/kg/d [75]
5% (1/21) [75] 14 m# [75] VPA + CZP + CLB 
[75]
57% [82] 80% [75] SUDEP [92]
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Agent or 
medication
Main action for treatment Dosage in the 
treatment
Responder rate 
(>50% reduction)
Retain 
period 
(year)
Retain combination 
remedy
Aggravation rate 
(>25% increase)
Cause of death 
(SE or SUDEP*)
Carbamazepine 
(CBZ)
Sodium channel blocker [91] 200–900  
mg/day [81]
9% [76] 0.9–>20 [81] VPA CLB STP ZNS 
LEV CLN TPM PHT 
[81]
33% [81] 71% [82]
21% [76]
SUDEP, SE [81]
Oxcarbazepine 
(OXC)
Sodium channel blocker [91] 600–1200  
mg/day [81]
Withdrawal + 
complete stop
0.1–>20 [81] VPA CBZ ZNS LEV 
CLN PHB [81]
72% [82] SUDEP [81]
Verapamil Voltage-gated calcium 
channel blocker [83]
1.5 mg/kg/d 
[83]
2/2 [83] 13–>20 m# VPA TPM PHT ETS† 
[83]
Clemizole H1 antagonist [88] 100 μM swim 
bath (zebrafish)
Significant reduce 
seizure behavior
Single dose Monotherapy [88]
Methylphenidate Increase dopamine release 
(rat) [89]
0.5–2.0 mg/kg 
i.p. [89]
Significant 
improvement
Single dose Monotherapy [89]
*SUDEP, sudden unexpected death in epilepsy; SE, status epilepticus.
#m: month.
†ETS, ethosuximide.
Table 1. The commonly used AEDs and the experimental therapies that have been applied in the treatment of Dravet syndrome.
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led to depolarizing the postsynaptic neurons [99]. Because Dravet syndrome would be treated 
intensively with multiple AEDs for a long time, the multifaceted mechanisms might involve the 
AED resistance during the disease development. They could be the pathological alteration of 
the target cells at cellular/molecular level (downregulation of KCC2 in the pyramidal cells) or 
the overexpression of multidrug transporter genes that code ATP-binding cassette transporters 
1–4 (ABCB1-4) in the epileptogenic zone (hippocampal sclerosis) [100]. The research interests 
might arise from those points in the future neuroscience and epileptology fields.
8. Conclusions
Dravet syndrome, an intractable epilepsy syndrome, affects the initially normal infants with 
febrile or non-febrile seizures, myoclonic seizures, hemiclonic seizures, and developmental 
delay. The SCN1A gene mutations are frequently found in patients with Dravet syndrome with 
“severe” genotypes, such as truncation or pore-region missense mutations. The SCN1A haplo-
deficiency mice display spontaneous seizures, cognitive impairment, and premature death, sim-
ilar to human clinical phenotype of Dravet syndrome. The electrophysiological findings indicate 
that the parvalbumin-expressing interneurons in those mice are dysfunctional and hypoexcit-
able. The selective dysfunction of PV interneurons causes the imbalance of excitatory and inhibi-
tory control to the principal neurons and neuronal network. The immunostaining has confirmed 
that Na
v
1.1 highly expresses at the axon initial segment of PV interneurons. Due to the complex 
and dynamic plasticity of AIS and the adaptation response of ion channels to neuronal activity, 
the Na
v
1.1 functioning within the AIS plasticity of PV interneurons and mutant pathogenesis 
remains unknown and would bring out the intensive studies in future. Patients with Dravet syn-
drome are always treated with multiple AEDs with disappointing outcome (Table 1). The most 
commonly used and retained AED in the treatment is valproate. The most evidently effective 
medication is bromide. With the aim to optimize the pharmacological treatment and encourage 
the earlier intervention to neurological development, the early genetic screening test of SCN1A 
gene is recommended to the possible patients with Dravet syndrome. Patients with Dravet syn-
drome should avoid the sodium channel blockers to prevent greater extent inhibition of Na
v
1.1 
function that potentially worsens the seizures. We expect that the more promising results would 
be generated in the experimental therapy studies of Dravet syndrome and provide the valuable 
resources to help the patients with Dravet syndrome and overcome the devastating disease.
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